Mast Therapeutics (MSTX) Reports In-Line Q4 Loss

Mast Therapeutics (NYSE: MSTX) reported Q4 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Mast Therapeutics (MSTX) click here.

You May Also Be Interested In

• BofA sees an "enhanced buying opportunity" in this memory stock
• Standard Motor Products (SMP) Misses Q2 EPS by 3c
• Coinbase (COIN) PT Lowered to $185 at Freedom Broker